Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3?)
Product Code
AMS.79853
$12,065.00
Order Support
- Email: [email protected]
Order Support
- Email: [email protected]
Order Support
-
T: +1 (800) 987 0985 (toll free)
-
Email: [email protected]
Order Support
-
Email: [email protected]
Shipping Information
-
Delivery charges will be calculated during checkout
Product Updates
-
Keep up to date with product offers, resources and news
Anti-CD19 CAR/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR and NFAT-luciferase reporter. It is made from the anti-CD19 CAR lentivirus ( Bioscience #79851). The reporter cell line has been validated for anti CD19-CAR expression by FACS, and for luciferase reporter activation stimulated by target cells including CD19/CHO recombinant cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing in primary T cells.
Anti-CD19 CAR consists of anti-CD19 scFv linked to 3rd generation CAR (Chimeric Antigen Receptor) containing CD28, 4-1BB co-stimulatory domains, and CD3? signaling domain.
Anti-CD19 CAR consists of anti-CD19 scFv linked to 3rd generation CAR (Chimeric Antigen Receptor) containing CD28, 4-1BB co-stimulatory domains, and CD3? signaling domain.
| SKU | AMS.79853 |
|---|---|
| Size | 2 vials |
| Application | • Validate different CAR designs and constructs for their specificity, efficacy and potency before proceeding into patient-derived primary T cells. • Predict the Mechanism of Action (MOA) of CAR. • Intracellular co-stimulatory and activati |
| Storage | Immediately upon receipt, store in liquid nitrogen. |
| Shipping Temp | -80C |
| Supplier Name | BPS |